Last reviewed · How we verify

Fibrin Sealant (Artiss)

Nguyen, Davis B., M.D. · FDA-approved active Small molecule

Fibrin Sealant (Artiss) forms a fibrin clot by combining thrombin and fibrinogen to achieve hemostasis and tissue adhesion.

Fibrin Sealant (Artiss) forms a fibrin clot by combining thrombin and fibrinogen to achieve hemostasis and tissue adhesion. Used for Hemostasis and tissue adhesion during surgery, Bleeding control in cardiovascular, general, and orthopedic surgical procedures.

At a glance

Generic nameFibrin Sealant (Artiss)
SponsorNguyen, Davis B., M.D.
Drug classFibrin sealant
TargetFibrinogen; thrombin substrate
ModalitySmall molecule
Therapeutic areaSurgery/Hemostasis
PhaseFDA-approved

Mechanism of action

Artiss is a two-component fibrin sealant that mimics the final stages of the coagulation cascade. When thrombin and fibrinogen components are mixed, thrombin enzymatically converts fibrinogen to fibrin monomers, which polymerize to form a stable clot. This creates both hemostatic and adhesive properties, allowing it to seal tissues and control bleeding during surgical procedures.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: